VivoSeq
Gastroenterology

Diarrhea

128

Pipeline Programs↗

21

Active Trials↗

52

Companies Involved↗

Diarrhea is a highly competitive landscape with 128 programs across 52 companies. The most active players are Ipsen, Seres Therapeutics, Inc., Ferring. 23 therapies are approved with 38 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

30/100

Mech. Concentration

7/100

Completion Rate

80/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

1 program

Phase 1S

Seres Therapeutics, Inc.

1 program

Phase 1Ferring logo

Ferring

2 programs

Phase 2R

RedHill Biopharma Limited

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2D

Dynogen Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical19

Rifaximin

Salix

Bivalent Oral Polio Vaccine

Centers for Disease Control and Prevention

Zinc

American Regent, Inc.

Zinc Supplement

Hamilton Health Sciences Corporation

Tigecycline

Prism Pharmaceuticals

Phase 115

Mirtazapine

Organon and Co

Racecadotril

McNeil AB

SER-155

Seres Therapeutics, Inc.

Smecta

Ipsen

Letrazuril

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 233

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Etrasimod

Pfizer

Lanreotide

Albireo, an Ipsen Company

Infliximab

Organon and Co

Glutamine

Sanofi

Phase 338

Nitazoxanide

Romark Laboratories L.C.

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Calcium Carbonate

Otsuka

Octreotide Acetate

Novartis

Simethicone

Portuguese Oncology Institute, Coimbra

Approved23

Octreotide

Sun Pharma

Loperamide

Kenvue Brands

Cholestyramine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Zidovudine

Bp Consulting, Inc

Rifampin

Sanofi

Analysis

Modality Breakdown

90%

Small molecule

120 of 133 classified programs — the dominant modality here.

10%ALL OTHERSVaccine54%Monoclonal antibody32%Peptide32%Protein / enzyme22%

Small molecule leads; the ring shows all 133 classified programs, each share of the total. Modality classified for 99% of 154 pipeline programs.

Analysis

Trial Status

175

clinical trials

Completed111 · 63%
Terminated19 · 11%
Unknown status15 · 9%
Withdrawn9 · 5%
Recruiting8 · 5%
Not yet recruiting6 · 3%
Other7 · 4%

Clinical Trials

Trial Activity

175 trials

Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 3·NCT04750070·135 enrolled
Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 4·NCT05677282·150 enrolled
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06801067·15 enrolled
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04038619·40 enrolled
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
Recruiting·MMayo Clinic·Phase 1·NCT06684470·20 enrolled
Fortified Oral Rehydration Therapy for Pediatric Diarrhea
Recruiting·—·Phase 1/2·NCT06137014·72 enrolled
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807593·10 enrolled
Treatment of Bile Acid Diarrhoea With Atorvastatin (BASTA): A Randomised, Double-Blind, Placebo-Controlled, Crossover, Investigator-Initiated Trial
Recruiting·AAsger Lund, MD·Approved·NCT07042165·20 enrolled
Stool Transplant to Control Treatment-related Diarrhea
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04883762·4 enrolled
Effect of Saccharomyces Boulardii CNCM I-745 (Sb) on Bloody Diarrhea in Children. A Double Blind, Randomized, Controlled Study ( Sb192-SUH )
Active, not recruiting·FFundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan·Phase 4·NCT07371819·140 enrolled
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06692907·72 enrolled
Comparison of Low Osmolar ORS and ReSoMal for Treating Acute Watery Diarrhea in Severely Malnourished Children Aged 6 Months to 5 Years
Active, not recruiting·UUniversity of Child Health Sciences and Children's Hospital, Lahore·N/A·NCT07026682·72 enrolled
A Mobile Health Tool to Improve Antibiotics Stewardship Among Village Doctors in Bangladesh
Active, not recruiting·—·Preclinical·NCT07538531·30 enrolled
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
Not yet recruiting·UUniversity of Calgary·Phase 2/3·NCT06337695·298 enrolled
Rash & Diarrhea Prophylaxis With Capivasertib
Not yet recruiting·—·Phase 2·NCT07426822·108 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)